Skip to content
10-Q

Quarterly Report

MiNK Therapeutics, Inc. INKT

0001193125-26-226804

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 4.98M sh
Shares Diluted Q1 2026 · Mar 31, 2026 4.8M sh
Shares Diluted Q1 2026 · Mar 31, 2025 3.96M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.73M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.34M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $9.53M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $13.36M
Cash And Equivalents Q1 2026 · Sep 30, 2025 $9.5M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$12.69M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$14.23M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$21.79M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$19.59M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.29M
Current Liabilities Q1 2026 · Dec 31, 2025 $13.03M
Current Assets Q1 2026 · Mar 31, 2026 $10.02M
Current Assets Q1 2026 · Dec 31, 2025 $13.85M
Total Assets Q1 2026 · Mar 31, 2026 $10.38M
Total Assets Q1 2026 · Dec 31, 2025 $14.24M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.57
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.70
Eps Basic Q1 2026 · Mar 31, 2026 −$0.57
Eps Basic Q1 2026 · Mar 31, 2025 −$0.70
Sga Expense Q1 2026 · Mar 31, 2026 $1.68M
Sga Expense Q1 2026 · Mar 31, 2025 $1.27M
Rd Expense Q1 2026 · Mar 31, 2026 $1.2M
Rd Expense Q1 2026 · Mar 31, 2025 $1.26M
Net Income Q1 2026 · Mar 31, 2026 −$2.74M
Net Income Q1 2026 · Mar 31, 2025 −$2.77M
Operating Income Q1 2026 · Mar 31, 2026 −$2.88M
Operating Income Q1 2026 · Mar 31, 2025 −$2.7M